# Monod Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/monod-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.monod.bio
- Total disclosed funding: $24M
- Latest round: Seed (Jun 10, 2022)
- Investors on record: 7

## About

Based in Washington, US, and founded in 2021 by COO David Shoultz, CSO Alfredo Quijano Rubio, David Baker, Andy (Hsien-Wei) Yeh, and Dave Johnson, Monod Bio, Inc. is a biotechnology company and a spin-off of the University of Washington’s Institute for Protein Design. The company develops biosensors that can detect antibodies, toxins, viral proteins, and other molecules. The biosensor responds by emitting light when recognizes its target.In October 2025, Monod Bio, Inc. received USD 750,000 grant funding from new investor Grand Challenges Canada. As of March 2022, Daniel-Adriano Silva is the CEO of Monod Bio, Inc.

Monod Bio, Inc. develops de novo protein biosensors that emit light when detecting targets, such as antibodies, toxins, viral proteins, and other molecules.

The company plans to use its proceeds from December 2021 funding to generate new biosensors for additional targets in health and biotechnology, expand its platform, and build prototypes to recognize targets in real-world applications. Monod Bio, Inc. also plans to hire protein biochemists and engineers, build its own space in Seattle, and increase its employee count by around 15 to 20 by the end of 2022.

## Funding rounds

- Seed, Jun 10, 2022, $24M — Washington Research Foundation, Matrix Capital, Sahsen Foundation, Boom Capital Ventures, Cercano Management, Global Health Investment Advisors, Pack Ventures

## Investors

- Washington Research Foundation — Seed
- Matrix Capital (https://capitalatlas.ai/funds/matrix-capital) — Seed
- Sahsen Foundation — Seed
- Boom Capital Ventures — Seed
- Cercano Management (https://capitalatlas.ai/funds/cercano-management) — Seed
- Global Health Investment Advisors — Seed
- Pack Ventures (https://capitalatlas.ai/funds/pack-ventures) — Seed